project id: TCGA-UCEC; case submitter id: TCGA-PG-A915; source center: 23; state: released; a260 a280 ratio: 1.89; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.63; rna integrity number: 9.0; age at index: 60; days to birth: -22119; ethnicity: not hispanic or latino; gender: female; race: black or african american; vital status: Alive; year of birth: 1953; age at diagnosis: 22119; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 249.0; figo stage: Stage IA; icd 10 code: C54.1; last known disease status: not reported; morphology: 8441/3; primary diagnosis: Serous cystadenocarcinoma, NOS; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; site of resection or biopsy: Endometrium; synchronous malignancy: No; tissue or organ of origin: Endometrium; tumor grade: Not Reported; year of diagnosis: 2013; treatment or therapy: no; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 238; initial weight: 410.0; sample id: caffe64c-1fb0-4229-b355-4b798d9506b0; sample submitter id: TCGA-PG-A915-01A; portion id: 77a4a074-94eb-43ec-a09d-b8be8e24f1bc; portion submitter id: TCGA-PG-A915-01A-11; slide id: a1661cc6-b413-4413-bf28-6d7409f6b0e3; slide submitter id: TCGA-PG-A915-01A-01-TSA; percent lymphocyte infiltration: 0.0; percent monocyte infiltration: 0.0; percent necrosis: 0.0; percent neutrophil infiltration: 0.0; percent normal cells: 0.0; percent stromal cells: 10.0; percent tumor cells: 90.0; percent tumor nuclei: 95.0; section location: TOP;